DATABASE &DRUG INTERACTIONS CORE There is a pressing need for a data base that contains relevant quantitative information on combinations of drugs of abuse. The Center for Substance Abuse Research (CSAR) of Temple University is proposing this effort as a new core activity in the Center activities that will be directed by RJ Tallarida. Dr. Tallarida has studied and published extensively in the area of drug combinations That effort, coupled with his numerous worldwide publications on drug combinations, is the basis of new component in this grant renewal application. Many drug combinations are well known for their approved use as well as their use on the street, (e.g., fentanyl + cocaine, heroin + methamphetamine, etc, and extensive combinations that involve alcohol or marijuana). We propose the addition of this core activity that will undertake the development of a data base derived from publications of laboratory-based studies and human use that include drug combinations of special relevance. By that we mean the legitimate medical use of a drug combination as well as common """"""""street combinations"""""""". The main objective is to search world wide and classify interactions as synergistic, sub-additive or simply additive. This will be accomplished from a newly created website, accessible by all, from our Center on Substance Abuse Research Investigators who study combinations of drugs of abuse are usually guided by awareness of those combinations that are common in street use. The patterns of such drug abuse are well known among law enforcement and regulatory agencies, and it is well documented that many-in fact, all, are potentially dangerous combinations. The danger is enhanced when the drugs interact synergistically in some toxic endpoint. It is therefore especially important to have precise quantitative information on such unusual interactions among these agents that are used recreationally and illegally.
Combination drug use is common in ethical medical usage and in street use. Most often a medical combination is used in order to take advantage of different mechanisms of action in achieving a therapeutic objective. In the ideal situation the use of a drug combination allows lower doses (and less toxicity) of the individual agents. Whether the objective is directed to street use or approved medical use it is important to have quantitative information on the drug combinations, especially synergistic toxic interactions.
|Ward, Sara Jane; Castelli, Francesca; Reichenbach, Zachary W et al. (2018) Surprising outcomes in cannabinoid CB1/CB2 receptor double knockout mice in two models of ischemia. Life Sci 195:1-5|
|Liu, Jeffrey J; Sharma, Kirti; Zangrandi, Luca et al. (2018) In vivo brain GPCR signaling elucidated by phosphoproteomics. Science 360:|
|Oliver, Chicora F; Simmons, Steven J; Nayak, Sunil U et al. (2018) Chemokines and 'bath salts': CXCR4 receptor antagonist reduces rewarding and locomotor-stimulant effects of the designer cathinone MDPV in rats. Drug Alcohol Depend 186:75-79|
|Zewde, Ashenafi Mebratu; Yu, Frances; Nayak, Sunil et al. (2018) PLDT (planarian light/dark test): an invertebrate assay to quantify defensive responding and study anxiety-like effects. J Neurosci Methods 293:284-288|
|Rom, Slava; Zuluaga-Ramirez, Viviana; Reichenbach, Nancy L et al. (2018) Secoisolariciresinol diglucoside is a blood-brain barrier protective and anti-inflammatory agent: implications for neuroinflammation. J Neuroinflammation 15:25|
|Ramirez, Servio H; Andrews, Allison M; Paul, Debayon et al. (2018) Extracellular vesicles: mediators and biomarkers of pathology along CNS barriers. Fluids Barriers CNS 15:19|
|Brailoiu, Eugen; Barlow, Christine L; Ramirez, Servio H et al. (2018) Effects of Platelet-Activating Factor on Brain Microvascular Endothelial Cells. Neuroscience 377:105-113|
|Barbe, Mary F; Massicotte, Vicky S; Assari, Soroush et al. (2018) Prolonged high force high repetition pulling induces osteocyte apoptosis and trabecular bone loss in distal radius, while low force high repetition pulling induces bone anabolism. Bone 110:267-283|
|Gentile, Taylor A; Simmons, Steven J; Barker, David J et al. (2018) Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine. Addict Biol 23:247-255|
|Hicks, Callum; Huang, Peng; Ramos, Linnet et al. (2018) Dopamine D1-Like Receptor Agonist and D2-Like Receptor Antagonist (-)-Stepholidine Reduces Reinstatement of Drug-Seeking Behavior for 3,4-Methylenedioxypyrovalerone (MDPV) in Rats. ACS Chem Neurosci 9:1327-1337|
Showing the most recent 10 out of 343 publications